Testing Obeticholic Acid for Familial Adenomatous Polyposis

Colorectal Carcinoma Clinical Trial

Official title:

A Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce Intestinal Polyp Burden in Familial Adenomatous Polyposis (FAP)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05223036
• Other study ID #: NCI-2022-00341
• Secondary ID: NCI-2022-0034120
• Status: Recruiting
• Phase: Phase 2
• Start date: January 19, 2023
• Est. completion date: February 21, 2026

Study information

• Verified date: April 2024
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase IIa trial investigates if giving obeticholic acid (OCA) is safe and has a beneficial effect on the number of polyps in the small bowel and colon in patients with familial adenomatous polyposis (FAP). FAP is a rare gene defect that increases the risk of developing cancer of the intestines and colon. OCA is a drug similar to a bile acid the body makes. It is fluid made and released by the liver. OCA binds to a receptor in the intestine that is believed to have a positive effect on preventing cancer development. OCA has been effective in treating primary biliary cholangitis (PBC), a liver disease, and is approved by the Food and Drug Administration (FDA) for use at a lower dose (10 mg). There have been studies showing that OCA decreases inflammation and fibrosis. However, it is not yet known whether OCA works on reducing the number of polyps in patients with FAP.

Description:

PRIMARY OBJECTIVE:

I. To evaluate the effect of treatment with OCA versus treatment with placebo on duodenal polyp burden (sum of polyp diameters) in participants with FAP.

SECONDARY OBJECTIVES:

I. To assess the safety profile of treatment with OCA versus placebo in participants with FAP.

II. To evaluate the effect of treatment with OCA versus placebo on rectal and pouch polyp burden (sum of polyp diameters) in participants with FAP.

III. To assess the effect of treatment with OCA versus placebo on polyp burden (absolute number) in the duodenum of participants with FAP.

IV. To assess the effect of treatment with OCA versus placebo on polyp burden (absolute number) in the rectum and rectal pouch of participants with FAP.

V. To evaluate the effect of treatment with OCA versus placebo on serum levels of fibroblast growth factor-19 (FGF19) and 7 alpha-hydroxy-4-cholesten-3-one (7AC4, also known as C4) in participants with FAP.

VI. To determine the effects of treatment with OCA versus placebo on gene expression in duodenal, rectal pouch, and rectal adenomas and uninvolved mucosa in participants with FAP:

VIa. Identify differentially expressed genes between duodenal and colorectal adenomas and uninvolved tissue at baseline and post-intervention for participants who received OCA or placebo; VIb. Quantify the effect of OCA on the expression of downstream targets of FXR in adenomas and uninvolved tissue; VIc. Quantify the effect of OCA on the expression of cancer stem cell markers (e.g. LGR5, ASCL2, LRIG, BMI) and intestinal stem cell markers (e.g. Villin, KRT20, MUC, LYZ) in adenomas and uninvolved tissue.

VII. To evaluate the cell-type specific effects of treatment with OCA versus placebo on gene expression and abundance in duodenal, rectal pouch, and rectal adenomas and uninvolved mucosa in participants with FAP via single-cell transcriptomics.

VIII. To evaluate the effect of treatment with OCA versus placebo on microbiome diversity in duodenal, rectal pouch, and rectal adenomas and uninvolved tissue in participants with FAP.

VIIIa. Compare alpha- and beta-diversity analysis and identify differential abundance in adenomas and uninvolved tissue.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive OCA 25 mg orally (PO) once daily (QD) for 6 months in the absence of unacceptable toxicity. Patients also undergo gastrointestinal (GI) endoscopy with biopsy and collection of blood samples at screening and on study.

ARM II: Patients receive matching placebo PO QD for 6 months in the absence of unacceptable toxicity. Patients also undergo GI endoscopy biopsy and collection of blood samples at screening and on study.

After completion of the study treatment, patients are followed within 14-21 days.

Other known NCT identifiers

• NCT05112822

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: February 21, 2026
• Est. primary completion date: January 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants must have a diagnosis of phenotypic FAP with disease involvement of the duodenum and rectum as defined by:

• Genetic diagnosis: APC germline mutation (with or without family history) or obligate carrier

• Clinical diagnosis: FAP phenotype with > 100 adenomas in large intestine and participant has a family history of FAP

• Clinical diagnosis: FAP phenotype who are status post colectomy for polyposis, participant has a family history of FAP, and 2 FAP experts agree to the diagnosis

• Attenuated FAP diagnosis: APC germline mutation required

• Participants must have no evidence of active or recurrent invasive cancer for 6 months prior to screening and must be at least 6 months from any prior cancer-directed treatment (such as surgical resection, chemotherapy, immunotherapy, hormonal therapy or radiation)

• Age >= 18 years. Because no dosing or adverse event (AE) data are currently available on the use of OCA in participants < 18 years of age, children are excluded from this study but will be eligible for future pediatric trials, if applicable

• Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)

• Hemoglobin >= 10 g/dL or hematocrit >= 30%

• Leukocyte count >= 3,500/microliter

• Platelet count >= 100,000/microliter

• Absolute neutrophil count >= 1,500/microliter

• Creatinine clearance (calculated if measured is not available) >= 30 mL/min/1.73m2

• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x the institutional upper limit of normal (ULN)

• Total bilirubin =< 1.0 x ULN

• Alkaline phosphatase =< 1.5 x ULN

• Gamma-glutamyl transferase (GGT) =< 1.5 x ULN

• Presence of Spigelman stage II or III duodenal polyposis at screening

• Presence of intact rectum or ileo-rectal anastomosis (IRA) or ileal pouch-anal anastomosis (IPAA) or end ileostomy

• Participants must have a negative test result for human immunodeficiency virus (HIV); if tested within the past 6 months, result will be accepted without repeating the test

• Participants must have negative test for hepatitis C virus (HCV) and B virus (HBV)

• Willing and able to adhere to the prohibitions and restrictions specified in the final approved protocol

• The effects of OCA on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, throughout the duration of study participation, and for at least 6 months after receiving the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately

• Willingness to moderate alcohol intake (consuming no more than 1 or 2 alcoholic drinks per day for women and men, respectively)

• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Prior use of study drug

• Duodenal or rectal/pouch polyp burden that is not quantifiable

• Histologically-confirmed high-grade dysplasia or cancer on biopsy at screening

• Individuals with active, known or suspected chronic liver disease including cirrhosis, nonalcoholic steatohepatitis (NASH) with liver fibrosis, NASH with cirrhosis, primary sclerosing cholangitis, biliary atresia

• Individuals with cholelithiasis or choledocholithiasis; acute cholecystitis (defined by a syndrome of right upper quadrant pain, fever, and leukocytosis associated with gallbladder inflammation diagnosed within the prior 6 weeks); or biliary obstruction (defined by extrahepatic cholestasis)

• Individuals with a history of pancreatitis or presence of pancreatic abnormalities suggestive of increased risk of pancreatitis

• Individuals with hepatic steatosis and velocity > 1.7 meters/second (m/s) as determined by liver ultrasound elastography

• Individuals with hyperlipidemia not well controlled with the use of pharmacotherapy and/or dietary modifications

• History of severe, progressive, or uncontrolled renal, genitourinary, hepatic, hematologic, endocrine, cardiac, vascular, pulmonary, rheumatologic, neurologic, psychiatric, or metabolic disturbances, or signs and symptoms thereof

• Pregnant, breast-feeding, or women of childbearing potential unwilling to use a reliable contraceptive method. Pregnant women are excluded from this study because OCA is an agent with unknown effects on the developing human fetus. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with OCA, breastfeeding should be discontinued if the mother is treated with OCA

• Known hypersensitivity, allergies, or intolerance to the study drug or compounds of similar chemical or biologic composition

• Any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with participant's safety, obtaining informed consent, or compliance to the study procedures

• Participants may not be receiving any other investigational agents

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

• Individuals with active and untreated hepatitis C virus (HCV) and/or or hepatitis B virus (HBV) infection

• Individuals with HIV infection are eligible for participation if:

• CD4+ count >= 300/uL

• Viral load is undetectable

• Receiving highly active antiretroviral therapy (HAART) without known or suspected drug interactions with OCA

• Consultation with the participant's infectious disease specialist may be obtained

• Individuals taking the drugs listed below may not be randomized unless they are willing to stop the medications (and possibly change to alternative non-excluded medications to treat the same conditions) no less than 5 half-lives days prior to starting OCA or placebo on this study. Consultation with the participant's primary care provider may be obtained but is not required. The use of the following drugs or drug classes is prohibited during OCA/placebo treatment:

• Investigational agents

• Bile acid sequestrants (bile acid binding resins): cholestyramine, colestipol, or colesevelam

• Bile salt efflux pump (BSEP) inhibitors

• Clozapine

• Theophylline derivatives

• Tizanidine

• Warfarin

• Hepatotoxic drugs such as amiodarone, sodium valproate, certain herbal/dietary supplements, and long-term doxycycline or tetracycline

Related Conditions & MeSH terms

• Adenomatous Polyposis Coli
• Attenuated Familial Adenomatous Polyposis
• Carcinoma
• Colorectal Carcinoma
• Colorectal Neoplasms
• Familial Adenomatous Polyposis
• Nasopharyngeal Neoplasms

Intervention

Procedure:
• Biopsy
Undergo biopsy
• Biospecimen Collection
Undergo collection of blood samples
• Gastrointestinal Endoscopy
Undergo GI endoscopy

Biological:
• Obeticholic Acid
Given PO

Drug:
• Placebo Administration
Given PO

Other:
• Questionnaire Administration
Ancillary studies

Locations

Country	Name	City	State
Puerto Rico	University of Puerto Rico	San Juan
United States	University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Cleveland Clinic Foundation	Cleveland	Ohio
United States	M D Anderson Cancer Center	Houston	Texas
United States	Mayo Clinic in Arizona	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage change in duodenal polyp burden	Change from baseline will be summarized by treatment arm. The difference in change from baseline between active treatment arms and the placebo arm will also be summarized.	Baseline to 6 months
Secondary	Incidence of adverse events	Will summarize adverse events for each group by grade and study drug attribution using descriptive statistics.	Up to 21 days after completion of treatment
Secondary	Absolute differences in the levels of serum FGF19 and C4	Differences in the median serum levels of FGF19 and C4 between treatment arms will be compared.	Baseline to 6 months
Secondary	Percentage change in the number of duodenal polyps	Will use parametric models to evaluate the absolute and/or relative changes from baseline of these measures between obeticholic acid (OCA) and placebo groups.	Baseline to 6 months
Secondary	Percentage change in the number of colorectal, rectal/pouch polyps	Will use parametric models to evaluate the absolute and/or relative changes from baseline of these measures between OCA and placebo groups.	Baseline to 6 months
Secondary	Percentage change in colorectal, rectal/pouch polyp burden	Will use parametric models to evaluate the absolute and/or relative changes from baseline of these measures between OCA and placebo groups.	Baseline to 6 months
Secondary	Changes in gene expression (messenger ribonucleic acid) profiles of adenomas and normal mucosa	Will apply methods such as the beta-uniform mixture (BUM) model, the Wilcoxon rank-sum test with empirical Bayes, and the significance analysis of microarrays (SAM) to control the first degree relative (FDR).	Baseline to 6 months
Secondary	Changes in the microbiome of adenomas and normal mucosa	Will apply methods such as the BUM model, the Wilcoxon rank-sum test with empirical Bayes, and the SAM to control the FDR.	Baseline to 6 months
Secondary	Future candidate biomarkers measured by genomic and transcriptomic platforms in residual tissue biopsies of adenomas and normal mucosa	Will apply methods such as the BUM model, the Wilcoxon rank-sum test with empirical Bayes, and the SAM to control the FDR.	At 6 months